CSQR entered the week as something of a debut — at least on analyst scorecards — with eight firms simultaneously initiating coverage on August 10, flooding the Street with fresh opinions on a stock that just logged a 7.7% weekly gain.
The wave of initiations tells the core story this week. Most of the Street lined up bullish: Jefferies opened with a Buy and a $29 target, Bernstein came in at Outperform with $27, Morgan Stanley set Overweight at $26, and BofA swung the widest with a Buy and a $46 target — a level that stands roughly double the current price at $22.36. The outlier was JP Morgan, which initiated at Neutral with a $24 target, barely above where the stock is already trading. Strip out BofA's outlier, and the pack of targets clusters between $24 and $29, implying modest upside from current levels. The consensus mean sits at $28.50. The Street is broadly constructive, but not uniformly so — JP Morgan's neutral stance suggests at least one major firm sees the post-IPO price as adequately reflecting near-term prospects.
The borrow market is not sending a bearish signal. Availability is extremely loose at around 2,460% — meaning shares available to borrow dwarf the current short interest by a factor of roughly 24. Short interest itself is thin, running just under 1.3 million shares with no float percentage calculable given incomplete float data. Days to cover clocks at one day, per the most recent FINRA fortnightly data. Cost to borrow has risen about 44% week-on-week to 3.2%, but the absolute level remains low. This is not a stock where short sellers are pressing hard. The ORTEX short score of 29.5 corroborates that read — it has barely moved across the past two weeks, hovering in a narrow band between 28.5 and 30.6.
The more striking data point is on the insider and institutional side. In mid-July, insiders and early stakeholders committed heavily at the $21 IPO price. The CEO alone purchased 3.57 million shares for roughly $75 million. The CFO bought $8 million worth, the COO $5.6 million, and the Chief Legal Officer nearly $8.8 million — all at $21. Directors added smaller lots. Net insider buying over the 90-day window totals approximately 4.65 million shares worth $97.7 million. That is a meaningful vote of confidence from the people closest to the business. Brookfield, both through its Wealth Solutions arm and the parent, each reported 3 million shares — a combined position worth roughly $134 million at current prices — per the July 16 filing.
The stock's reaction to its first earnings report as a public company is also worth noting. On August 6, results triggered a 6.1% single-day gain. The next scheduled print is November 6.
What to watch: whether the BofA $46 target — an outlier that nearly doubles its peers' views — attracts scrutiny or revisions in the weeks ahead, and whether the stock can sustain its post-IPO price discovery above the JP Morgan Neutral waterline of $24.
See the live data behind this article on ORTEX.
Open CSQR on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
